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As the replication pattern of leukemogenic PTLVs possesses a strong pathogenic impact, we investigated HTLV-2 replication in vivo in
asymptomatic carriers belonging into 2 distinct populations infected by the same HTLV-2b subtype. They include epidemically infected American
blood donors, in whom HTLV-2b has been present for only 30 years, and endemically infected Bakola Pygmies from Cameroon, characterized by
a long viral endemicity (at least few generations). In blood donors, both the circulating proviral loads and the degree of infected cell proliferation
were largely lower than those characterizing asymptomatic carriers infected with leukemogenic PTLVs (HTLV-1, STLV-1). This might contribute
to explain the lack of known link between HTLV-2b infection and the development of malignancies in this population. In contrast, endemically
infected individuals displayed high proviral loads resulting from the extensive proliferation of infected cells. The route and/or the duration of
infection, viral genetic drift, host immune response, genetic background, co-infections or a combination thereof might have contributed to these
differences between endemically and epidemically infected subjects. As the clonality pattern observed in endemically infected individuals is very
reminiscent of that of leukemogenic PTLVs at the pre-leukemic stage, our results highlight the possible oncogenic effect of HTLV-2b infection in
such population.
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The retrovirus HTLV-2 has not been clearly associated with
the development of hematological malignancies. Only a few
reports have described lymphomas in HTLV-2 carriers (Farias
de Carvalho et al., 1997; Guitart, 2000; Poiesz et al., 2000). In
contrast, the virus has been found to be etiologically linked
with the development of neurological symptoms (Murphy et
al., 1997) and with susceptibility to certain bacterial and fungal
infections (Murphy et al., 1999). The predominant mode of0042-6822/$ - see front matter D 2005 Published by Elsevier Inc.
doi:10.1016/j.virol.2005.08.026
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1 ASG and VM contributed equally to this work.replication of primate T cell lymphotropic viruses (PTLVs) in
vivo is via the clonal expansion of the infected cell. Such a
mode of replication has been demonstrated for HTLV-1
(Mortreux et al., 2003), HTLV-2 (Cimarelli et al., 1996), and
STLV (Gabet et al., 2003a, 2003b). Such cell-associated
proviral multiplication explains the low level of genetic drift
of these viruses (Mortreux et al., 2003).
There are three main subtypes of HTLV-2. HTLV-2a and
HTLV-2b are both present in intravenous drug users (IDUs) in
Europe, the USA, Vietnam and in several native American
Indian or African tribes (Slattery et al., 1999), whereas HTLV-
2d was isolated from a Mbuti Efe Pygmy (Vandamme et al.,
1998). The phylogenetic distinctiveness of an additional
subtype, HTLV-2c, composed mainly of strains from Brazilian
Kayapo Indians and IDU from Sao Paulo, is less clear (Slattery06) 13 – 21
www.e
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infected with HTLV-2, corresponding respectively to endem-
ically and epidemically infected populations. HTLV-2 infection
is endemic in culturally and geographically isolated ethnic
tribes, American Indians in North America (Hjelle et al., 1993),
Central America (Lairmore et al., 1990) and peripheral regions
of South America (Biglione et al., 1993; Duenas-Barajas et al.,
1993; Ferrer et al., 1993; Ijichi et al., 1993), as well as in
Bakola and Efe Bambuti Pygmies in Central Africa (Gessain et
al., 1995; Goubau et al., 1992; Vandamme et al., 1998). These
populations are characterized by long viral endemicity time (at
least few generations) with breast feeding and sexual contacts
as the major routes of infection. Epidemically infected
individuals mainly correspond to IDUs in the USA, Europe
and Asia (Vandamme et al., 2000). This population is
characterized by a short viral endemicity (¨30 years) and by
needle sharing and sexual contacts as the major routes of
dissemination.
Recently, by using molecular phylogenies, Salemi et al.
investigated the population dynamics of HTLV-2 in IDUs and
endemically infected tribes (Salemi et al., 1999). Molecular
clock analysis showed that HTLV-2 has two different evolu-
tionary rates, with the molecular clock for the virus ticking
150–350 times faster in IDUs than in endemically infected
tribes. The present study was conducted in order to compare
HTLV-2 replication between individuals from both groups. To
this end, both the proviral loads and the clonal distribution of
circulating HTLV-2-infected cells were compared between
endemically infected Bakola Pygmies from Cameroon and
American blood donors with epidemic virus spread, both
populations being infected by the same HTLV-2b subtype, in
the absence of HIV co-infection.
Results
High proviral load in HTLV-2b endemically infected
individuals
The lower limit of detection was 1 copy per 5000 PBMCs
(0.02%). As shown in Table 1, we estimated the absolute copy
number of HTLV-2b proviral DNA per 100 PBMCs. Each
sample was analyzed in triplicate, and the values represented in
the table correspond to the mean viral copy number obtained
for each sample after 3 experiments. Although all analyzed
samples had circulating HTLV-2b sequences, as evidenced by
nested PCR (not shown), 24/43 (56%) were found to have
proviral loads under the detection threshold of our quantitative
PCR assay. These samples with very low HTLV-2b proviral
loads derived from 8 of the 13 blood donors (62%), whereas all
samples derived from the Bakola Pygmies displayed proviral
loads >0.02% (P = 0.003, Fisher’s Exact Test). Assuming a
proviral load of 0.02% for samples under the quantitative PCR
detection threshold, the copy numbers in US blood donors
varied from 0.02% to 2.11%; those of Bakola Pygmies varied
from 0.4% to 3.2%. The mean T standard error of mean (SEM)
and median of the copy numbers were 0.28% T 0.09% and
0.02% for US blood donors, and 1.52% T 0.29% and 1.51% forBakola Pygmies. The median copy number of Bakola Pygmies
was more than 75-fold higher than that of US blood donors.
The difference between Bakola Pygmy and blood donor
samples was statistically significant (P = 0.004, t test for
unpaired samples). In contrast, when the comparison was
restricted to samples with proviral loads 0.02%, there was no
significant difference in the mean circulating HTLV-2b copy
number between the 10 samples derived from endemically
(mean T SEM, 1.52% T 0.29%) and the 9 samples derived from
epidemically infected individuals (mean T SEM, 0.96% T
0.24%) (P = 0.3). DNA samples derived from 5 blood donors
were tested 5 times for HTLV-2b proviral loads using PBMCs
samples drawn at several years interval over a (¨10-year
period. Three were found repeatedly negative for HTLV-2b
quantitative PCR (<0.02%). One was found repeatedly positive
with low fluctuation of the proviral copy number between
samples (0.2%, 0.7%, 1.6%, 1.01% and 0.80%). The remaining
individual had 4 negative (<0.02%) and one positive samples;
this one corresponded to the first sample harvested and
displayed a low proviral load (0.04%).
Clonal expansion of HTLV-2b-infected cells in individuals with
high or low proviral loads
The HTLV-2b LMPCR detection threshold was 20 copies in
150,000 cells, meaning that each detected signal after run-off
analysis of quadruplicate LMPCR products corresponded to a
cluster of at least 20 cells sharing the same HTLV-2b
integration site and therefore belonging into the same clone.
The stochastic nature of HTLV-2b LMPCR (Cavrois et al.,
1995) was found to appear at HTLV-2b integration site
frequencies ranging between 20 and 1000 copies of the
HTLV-2b provirus per microgram of DNA (Fig. 1). Hence, a
quadruplicate LMPCR analysis of NlaIII digested plasmid
bearing an integrated HTLV-2b LTR showed that above 1000
copies (diluted in 1 Ag) detection was 4/4. At copy numbers
ranging from 20 to 125, 125 to 500 and 500 to 1000, detection
was 1/4, 2/4 and 3/4, respectively. Infected clones detected
once or twice after quadruplicate analysis were defined as
having a polyclonal pattern of replication, whereas those
detected more frequently, i.e., 3 or 4 times, were defined as
having oligoclonal distribution. Quadruplicate LMPCR (4 
0.5 Ag) was carried out with samples derived from 9 Bakola
Pygmies (9 samples) and 12 blood donors (27 samples).
Typical results from quadruplicate LMPCR analysis of HTLV-
2b integration in the DNA from infected individuals are shown
in Fig. 2. All 6 analyzed samples displayed signals each
corresponding to a cluster of cells sharing the same integration
sites, i.e., belonging in the same clone deriving from a unique
infected progenitor. No signal was observed with negative
controls (NC). Overall, the figure shows that there was a wide
variation in the number of detected clones between samples
(compare samples 670502 and PD303926), their distribution
being detailed in Table 1. In addition, the figure clearly
evidence that the frequency of detection varied from clone to
clone as some were detected 1, 2, 3 or 4 times. As the
frequency of detection represent the degree of clonal expan-
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variation in the degree of clonal expansion between clones. In
addition, as for the overall number of detected clones, their
degree of expansion varied between sample. Hence, 0 and 2Table 1
Initial characteristics, proviral loads and clonality of HTLV-2b infected cells in end
Status UCNa Age Gender Race/Ethnicity Risk/Route of
HTLV-2b
infection
Time from
contaminat
Bakola Pygmies
550602 30 F Pygmy Breast-feeding/
Sexual contacts
–
590102 55 F Pygmy Breast-feeding/
Sexual contacts
–
940701 36 M Pygmy Breast-feeding/
Sexual contacts
–
590101 58 M Pygmy Breast-feeding/
Sexual contacts
–
670502 60 F Pygmy Breast-feeding/
Sexual contacts
–
670802 36 F Pygmy Breast-feeding/
Sexual contacts
–
500102 50 F Pygmy Breast-feeding/
Sexual contacts
–
590303 10 M Pygmy Breast-feeding 10
670102 50 F Pygmy Breast-feeding/
Sexual contacts
–
330302 25 F Pygmy Breast-feeding/
Sexual contacts
–
Blood donors
301559 44 F Vietnamese No –
302298 54 M Hispanic >7 sexual
partners
18
303926 31 F Hispanic No –
316023 32 F White >7 sexual
partners
4
401243 32 F White >7 sexual
partners
9
501993 30 F Black >7 sexual
partners
7
100238 33 F Black Sex with
IDU
8
302276 45 F White >7 sexual
partners
14
304507 39 M Black IDU 18
304518 34 F White Transfusion 12
400322 36 F White Sex with
IDU
4oligoclonally expanded forms were respectively detected
samples derived from patient PD501686 and PD303926,
whereas 11 and 11 such clone were respectively present in
samples from patient 670502 and 550602. In fact, circulatingemically and epidemically infected individuals
ion
Duration
of follow-up
(years)
Proviral
loadsb
Overall number
of HTLV-2b
circulating clones
after quadruplicate
LMPCRc
Number of
clones detected
1 or 2 timesc
Number of
clones detected
3 or 4 timesc
2.03 22 12 10
1.87 15 6 9
0.4 15 12 3
2.64 26 14 12
0.57 27 18 9
0.84 40 29 11
0.65 33 24 9
1.24 15 7 8
1.77
3.2 28 16 12
<0.02 0 0 0
1.75 26 25 1
0.00 0.22 21 19 2
2.00 0.69 15 12 3
4.25 1.56
7.00 1.01
9.20 0.8 6 4 2
<0.02 0 0 0
0.00 <0.02 0 0 0
1.78 <0.02
4.47 <0.02 0 0 0
6.99 <0.02 0 0 0
9.88 <0.02 0 0 0
2.11 22 15 7
<0.02 0 0 0
<0.02 0 0 0
<0.02 0 0 0
<0.02 0 0 0
<0.02 0 0 0
<0.02 0 0 0
<0.02 0 0 0
0.43
<0.02 0 0 0
(continued on next page)
Status UCNa Age Gender Race/Ethnicity Risk/Route of
HTLV-2b
infection
Time from
contamination
Duration
of follow-up
(years)
Proviral
loadsb
Overall number
of HTLV-2b
circulating clones
after quadruplicate
LMPCRc
Number of
clones detected
1 or 2 timesc
Number of
clones detected
3 or 4 timesc
490046 58 M White Transfusion 21 0.00 <0.02 2 2 0
2.11 <0.02 6 6 0
4.54 <0.02 1 1 0
7.27 <0.02 0 0 0
9.17 <0.02 0 0 0
501686 51 F Indian
(North
American)
Transfusion 11 0.00 0.04 3 3 0
2.11 <0.02
4.53 <0.02 0 0 0
6.61 <0.02 3 3 0
8.82 <0.02 4 4 0
a UCN unique carrier number.
b per 100 PBMCs.
c per 150,000 PBMCs.
Table 1 (continued)
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36 samples (53%) (Fig. 2, Table 1). All 17 samples with
negative LMPCR results had a circulating proviral load
<0.02%. Five samples with proviral loads below the quantita-
tive PCR threshold were found to have a positive result after
LMPCR (Table 1). Of these, 4 displayed only 1 to 6 one-time
detected signals (mean T SEM, 3.2 T 0.97) after quadruplicate
experiments, whereas one had a unique two-time detected
clone. This result was consistent with the higher sensitivity of
LMPCR, when compared to real-time quantitative PCR. The
mean proviral load of samples having a negative LMPCR result
was 0.02% (assuming a 0.02% value for samples below the
detection threshold) versus 0.99% for those with a positiveFig. 1. Ligation-mediated PCR protocol used for amplifying 3V HTLV-2b integration
detection by quadruplicate IPCR.result. Although the ubiquitous glucose transporter GLUT-1,
the receptor for HTLV-1/2 retroviruses, is expressed by both
CD4+ and CD8+ T cells (Manel et al., 2003), the CD8+ subset
has been found to be the main reservoir for HTLV-2 in vivo
(Casoli et al., 1995; Ijichi et al., 1992). We therefore enriched
the cellular fraction in CD8+ T cells by negative selection, as
described in the Materials and methods section. This was
performed with 2 samples derived from 2 individuals (UCN
60689 and 61006) with proviral loads <0.02% and no
detectable clone of HTLV-2b positive cells after LMPCR.
The same procedure was applied to a sample having a positive
LMPCR result (UCN 60998) used as positive control. After
negative selection, purity, contamination and percentage ofsites. The inset represents the stochastic nature of HTLV-2b 3V integration site
Fig. 2. Ligation-mediated PCR analysis of HTLV-2b replication in peripheral
blood cells from endemically (A) and epidemically (B) infected individuals.
Each sample was analyzed in quadruplicate by LMPCR as detailed in the
Material and methods section. The molecular weight marker (M) was the
MWM  DNA. Carriers are identified by their unique carrier number (UCN).
NC, negative control. For each sample, the percentage of infected peripheral
blood mononuclear cells (PBMCs), as estimated by quantitative PCR, is given
between brackets.
Fig. 3. Ligation-mediated PCR analysis of HTLV-2b integration within the
DNA extracted from CD8+ T cells. PBMCs were enriched in CD8+ T cells by
negative selection, as described in the Materials and methods section. Carriers
are identified by their UCN. For each carrier, HTLV-2b integration is analyzed
in quadruplicate for both the PBMCs and CD8+ T cells. J-154 corresponds to a
positive control (DNA from an HTLV-2b cell line established from the PBMCs
of a Bakola Pygmy). And horizontal arrow identifies a faint signal obtained
with sample from carrier 501686.
A.-S. Gabet et al. / Virology 345 (2006) 13–21 17CD8+ T cell enrichment were, for samples derived from carriers
60689, 61006 and 60998, 82.28%, 0.01% and 514%; 89.77%,
0.03% and 504%; and 86.51, 0.09% and 474%, respectively.
DNA was extracted from enriched cellular fractions, and
LMPCR was performed as detailed in the Materials and
methods section. Typical results of the run-off analysis of
amplified products deriving from the DNA of CD8+ T cells are
shown in Fig. 3. After enrichment, 3 clones of HTLV-2b
positive cells could be evidenced for CD8+ cells derived from
blood donor 401243. One clone was detected once and two
were detected twice, with a clonal frequency of 2.1 103 and
1.3 102 per 100 PBMCs, respectively. Similarly, 4 HTLV-2b
positive clones could be evidenced for CD8+ cells deriving
from blood donor 501686. Two clones were detected once, and
one was detected twice, with a clonal frequency of 2.3 103
and 1.4 102 per 100 PBMCs, respectively. These values areconsistent with negative LMPCR results obtained with the
DNA deriving from whole PBMCs. Together, these results
suggest that circulating clones of HTLV-2b positive cells can
be found in all HTLV-2b-infected individuals, if CD8+
enrichment is done for those having very low proviral loads.
High level of infected T cell oligoclonal proliferation in
endemically infected HTLV-2b carriers
Having found a significantly higher circulating proviral load
in endemically than in epidemically HTLV-2b-infected indivi-
duals, we subsequently compared the clonal distribution of
integrated proviruses within circulating lymphocytes between
the 2 populations. Typical data concerning HTLV-2b integra-
tion sites in samples derived from 4 Bakola Pygmies and 4
blood donors are presented in Fig. 2 while Table 1 summarizes
the results obtained for the 21 HTLV-2b carriers studied. Ten of
the 27 samples derived from blood donors had positive
LMPCR results, whereas all 9 samples derived from Bakola
Pygmies displayed circulating clones of HTLV-2b positive
cells. Indeed, circulating clones of HTLV-2b positive cells
could be evidenced in 5/12 (42%) blood donors versus 9/9
(100%) Bakola Pygmies. This difference was statistically
significant (P = 0.007, Fisher’s Exact Test). It is evident from
Fig. 2 and Table 1 that, as for proviral loads, the degree of
clonal expansion of HTLV2b positive cells was significantly
higher in endemically infected individuals. After quadruplicate
LMPCR, the overall number of HTLV-2b positive clones was
significantly higher in Bakola Pygmies than in blood donors
(Fig. 2, Table 1). It ranged from 15 to 40 for the former (mean T
SEM, 24.56 T 2.91; median 26), and from 0 to 26 for the latter
(mean T SEM, 3.85 T 1.40; median 0.00, P < 104, Mann–
Whitney test). As the overall number of HTLV-2b positive
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ed cells were significantly higher in Bakola Pygmies: 15.33
versus 3.33, and 9.22 versus 0.52, respectively (P < 104 for
both, Mann–Whitney test). We next restricted the comparison
to the 19 samples having at least one detected clone after
LMPCR. The overall number of clones remained significantly
higher in Bakola Pygmies than in blood donors (24.56 versus
10.4, P = 0.004, Mann–Whitney test). However, the mean
number of polyclonally expanded cells was not significantly
different between Bakola Pygmies and blood donors (12.5
versus 7.8, P = 0.65, Mann–Whitney test), whereas that of
oligoclonally expanded cells was significantly higher in
endemically infected individuals (14.8 versus 5.7, P < 104,
Mann–Whitney test). Therefore, these results demonstrated that
the higher circulating proviral loads that characterized endem-
ically infected individuals, when compared to epidemically
infected subjects, resulted from a significantly higher degree of
clonal expansion of circulating HTLV-2b-infected cells.Fig. 4. Persistent clonal expansion of HTLV-2b positive cells in vivo.
Quadruplicate LMPCR was carried out over time with samples derived from
carriers 303926 (A) and 501686 (B), as described in the Materials and methods
section. Persistent clones are identified by horizontal arrows.Persistent clonal expansion of HTLV-2b-infected cells over
time
DNA samples from PBMCs derived from the 5 blood
donors monitored for proviral loads over time were also tested
2–5 times (20 samples tested) for the clonality of HTLV-2b-
infected cells using samples drawn at several years interval
over a ¨10-year period. Typical results of LMPCR analysis of
samples harvested over time are shown in Fig. 4. Of the 3
blood donors with very low proviral loads over time (<0.02%),
2 (UCN 401243 and 302276), tested 4 and 5 times over a ¨10-
year period, were found repeatedly negative for HTLV-2b
quadruplicate LMPCR. In the remaining blood donor with
repeatedly negative quantitative PCR results (UCN 490046),
clones of HTLV-2b positive cells could be detected in the first
analyzed sample as well as in those harvested 2.1 and 4.5 years
later, whereas the last 2 samples, harvested at 7.3 and 9 years,
gave negative results. For this blood donor, the first, second
and third samples with positive LMPCR results displayed 2, 6
and 1 clones of HTLV-2-infected cells, respectively, each of
these being detected only once after quadruplicate experiments
and therefore having a clonal frequency of 20–125/150,000
(Table 1). The blood donor with repeatedly positive quantita-
tive PCR results (UCN303926, Fig. 4A) was tested for
clonality on three occasions, at enrollment then 2 and 8.2
years later. All 3 samples displayed positive LMPCR results
with a pattern of oligoclonal expansion of HTLV-2b-infected
cells. It is clear from Fig. 4A that some of these HTLV-2b
positive clones were persistently detected over a 2- to 8-year
period of time. The remaining blood donor tested over time
(UCN 501686) had a proviral load of 0.04% in the first
harvested sample, whereas the remaining 4 samples, harvested
over a 9-year period, had very low proviral loads (<0.02%)
(UCN501686, Fig. 4B). Three clones of HTLV-2b positive
cells were detected in the first samples, all being detected only
once. Three additional samples with very low proviral loads
harvested over time were also tested by LMPCR. No signal
was observed at 5.5 years, whereas 3 and 4 clones were
detected at 7 and 9 years, respectively, all being detected only
once after quadruplicate experiments. Therefore, as for other
PTLV, the pattern of HTLV-2b replication in vivo involves the
persistent clonal expansion of infected cells. As estimated from
their frequency of detection, the degree of clonal expansion of
persistently detected clones could vary over time. However, as
for proviral loads, there was no significant correlation between
the pattern of clonal expansion and the duration of follow-up in
these 5 blood donors.
Discussion
The study shows that the pattern of HTLV-2b replication in
vivo is strongly different between endemically infected Bakola
Pygmies and epidemically infected blood donors. The former
regularly display high proviral loads resulting from the
extensive proliferation of infected cells, whereas the latter
have low or very low proviral loads associated with a weak
degree of clonal expansion.
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reservoir for HTLV-2 in vivo (Casoli et al., 1995; Ijichi et al.,
1992), permitted to detect clones of infected cells in individuals
with very low proviral loads. Accordingly, rather than being
restricted to carriers with high proviral loads (Cimarelli et al.,
1996), clones of HTLV-2b positive cells seem to be present in
all infected individuals. Therefore, HTLV-2b replicates as other
PTLV, i.e., by a combination of reverse transcription with clonal
expansion. However, 62% of HTLV-2b-infected blood donors
displayed very low proviral loads (<0.02%) and the clonal
frequency of circulating HTLV-2b positive cells was less than
1.3 102% in 33.3% of the population studied. These values
clearly distinguish HTLV-2b carriers from other PTLV-infected
individuals or animals. Hence, for HTLV-1 (Gabet et al., 2000;
Nagai et al., 1998; Wattel et al., 1992), and STLV-1 (Gabet et
al., 2003a, 2003b), samples with less than 0.02% of infected
cells are exceptional (Nagai et al., 1998; Shinzato et al., 1991;
Wattel et al., 1992), and expanded cells with a clonal frequency
lower than 1.3% have never been observed to date, even in
asymptomatically infected organisms (Cavrois et al., 1996a,
1996b; Cavrois et al., 1998; Gabet et al., 2000, 2003a, 2003b;
Leclercq et al., 1998; Mortreux et al., 2001a, 2001b, 2003;
Wattel et al., 1995). Therefore, it appears that the replication of
HTLV-2b in vivo involves a significantly lesser degree of clonal
expansion than that of other PTLV, resulting in significantly
lower proviral loads. In vivo, HTLV-1 (Mortreux et al., 2001b,
2003) infected cells display a mutator phenotype with a level of
cellular genetic instability proportionate to their level of clonal
expansion. Accordingly, HTLV-1 carriers harboring a high level
of clonal expansion are more at risk to develop ATLL, as
demonstrated in the case of Strongyloides stercoralis infection
(Gabet et al., 2000) or infective dermatitis (Gabet et al., 2003a,
2003b). Accordingly, the low degree of clonal expansion of
HTLV-2b-infected cells in vivo might contribute to the lack of
HTLV-2b-associated malignancy, at least in the group of US
blood donors with very low circulating proviral loads. In fact,
the two present populations of HTLV-2b-infected individuals
could be easily distinguished on the basis of HTLV-2b
replication pattern in vivo. Endemically infected Bakola
Pygmies displayed a pattern of replication reminiscent of that
of HTLV-1-infected individuals at the pre-ATLL stage (Fig. 2).
A longer duration of intraindividual HTLV-2b infection in
endemically infected individuals could have accounted for the
different patterns of HTLV-2b replication between the two
populations. However, in the 5 blood donors followed over a
10-year period, there was no significant correlation between
time and proviral loads or clonal expansion. A more prolonged
period of infection might be necessary to influence HTLV-2b
replication in vivo. Alternatively, infection during infancy as via
breast feeding might constitute a pre-requisite for further
extensive replication of the virus. Other factors than the route
of transmission or the duration of the infection could have
accounted for the differences observed between endemically
and epidemically infected individuals. They might include the
evolution rate of the virus itself, host immune response, the
genetic background, co-infections, such as in the case of
strongyloidiasis with HTLV-1 or a combination thereof.HTLV-2b was only discovered 20 years ago, and hemato-
logical malignancy has not been found among infected
individuals in the United States as in Europe. However,
prospective studies on the possible higher incidence of
hematological diseases in isolated HTLV-2b-infected indivi-
duals such as Bakola Pygmies have not been performed. For
HTLV-1, early infection via breast feeding is a pre-requisite for
the subsequent development of ATLL, which typically occurs
after a 50- to 60-year period of latency (Blattner, 1989). As the
clonality pattern observed in endemically infected individuals
is reminiscent of that of HTLV-1-infected individuals at the
pre-ATLL stage (Fig. 2), our results highlight the possible
oncogenic effect of prolonged HTLV-2b infection in early
infected individuals.
Materials and methods
Samples studied
The materials consisted in 10 and 33 PBMC samples
deriving respectively from 10 endemically infected Bakola
Pygmies from Cameroon and 13 US blood donors with
epidemic virus spread. The Bakola Pygmies are an ethnic
group living in the area of Akok (Camo district), near Kribi in
the Ocean Department of southern Cameroon (Gessain et al.,
1995). Blood donors were recruited from five major US blood
donation centers (Baltimore/Washington, Detroit, Oklahoma
City, San Francisco and Los Angeles) participating in the
HTLV Outcomes Study (Orland et al., 2003). All participating
individuals were HIV-seronegative. Serological diagnosis of
HTLV-2 infection was carried out as previously described
(Gessain et al., 1995; Liu et al., 2001). For the HTLV-2 blood
donors, duration of infection was estimated by a weighted
analysis of risk factors and dates of these risk factors (Nass et
al., 1999) (Table 1). Restriction fragment length polymorphism
analysis of PCR product was performed to classify the virus
into the HTLV-2b subtype (Switzer et al., 1995), as previously
published (Liu et al., 2001). Five US blood donors were bled
on different occasions, including 3 donors from whom 40 ml of
blood was harvested for negative selection of CD4CD8+ T
lymphocytes. CD8+ T cell enrichment was achieved by
negative selection with the StemSep system.
Quantification of circulating HTLV-2b proviral loads
Circulating HTLV-2b proviral loads were measured by
quantitative LightCycler real-time PCR using 0.3 Ag of DNA
from blood diluted to a final volume of 20 Al. The reaction
mixture included polymerase (LightCycler Kit Fast Start DNA
Master Hybridization Probes; Roche), 2 mM MgCl2, 500 nM
primer HT2BQF (5V-AATAGCAGTGTGGCTTG-3V), posi-
tioned at 6116–6132, 500 nM primer HT2BQR (5V-
CCTGGGTAAGGTGGGA-3V), positioned at 6234–6249,
100 nM donor probe HT2BQP1 3V end labeled with fluorescein
(5V-GCCGGGACAGGTATCGC-FL), positioned at 6147–
6163, and 200 nM acceptor probe HT2BQP2 5V end labeled
wi th LC Red640 (5 V-LC Red640-GCGGAGTAA-
A.-S. Gabet et al. / Virology 345 (2006) 13–2120CAGGCTCCC-p) positioned at 6166–6183 (nucleotide co-
ordinates are numbered according to the HTLV-2 sequence
HTLV-II-Gab (Genbank reference: Y13051). Amplification
conditions were 95 -C for 8 min to activate the polymerase,
followed by 55 cycles at 95 -C for 10 s, 60 -C for 10 s and
72 -C for 10 s. In order to standardize the amount of DNA
subjected to quantification, we used the albumin gene as an
internal standard, as previously described (Gabet et al., 2000).
Semiquantitative linker-mediated PCR (LMPCR) amplification
of HTLV-2b extremities together with their 3V flanking
sequences
Two micrograms of DNAwas digested with 20 U of NlaIII in
1xNlaIII buffer for 3 h at 37 -C. One microgram of digested
DNA was ligated with 10 pmol of BIO1 primer (Wattel et al.,
1995) using 20 U of T4 DNA ligase in 40 Al for 16 h at 16 -C.
This step was followed by phenol/chloroform extraction and
precipitation. Ligated DNAwas amplified for 100 cycles using
the HT2-2 primer alone (5V-TTACCCCCTGCCCATAAAAT-
3V), positioned at 8425–8445. Conditions were 1  Stoffel
fragment of the Taq DNA polymerase buffer, 1.5 mM MgCl2,
10 pmol HT2-2, 200 AM of each dNTP and 10 U of Stoffel
fragment of the Taq DNA polymerase in a final volume of
100 Al. Thermal cycling parameters were 95 -C, 10 min;
100  (95 -C, 1 min; 58 -C, 1 min; 72 -C, 3 min) followed by
a final elongation step of 10 min at 72 -C. Ten microliters of this
linear PCR reaction was used in a classical PCR amplification
using the HT2-3 (5V-GCAAGGACAGTTCAGGAGGT-3V),
positioned at 8486–8505, and BIO4 (Wattel et al., 1995)
primer pair. Amplification conditions were as before with 40
pmol of each primer, again in a final volume of 100 Al. Thermal
cycling parameters were 95 -C, 10 min; 39  (95 -C, 1
min; 58 -C, 1 min; 72 -C, 3 min) followed by a final
elongation step of 10 min at 72 -C. The length polymor-
phism of HTLV-2 flanking sequences was studied by run-off
analysis, as described for HTLV-1 with an HTLV-2b specific
primer (5V-GGAGCGCAGCAAGGGCTAGGGC-3V) (position
8857–8879).
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